Related Experiment Video
Updated: Jun 12, 2026

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster
Published on: March 24, 2023
The Food and Drug Administration risk evaluation and mitigation strategy
1Care Service, H Lee Moffitt Cancer Center and Research Institute in Tampa, Florida 33612-9412, USA. david.craig@moffitt.org
Abstract:
The Food and Drug Administration Amendments Act of 2007 extended the agency's regulatory authority over drug products that have been shown to place patients at risk. This Act authorizes the FDA to require pharmaceutical manufacturers and distributors to ensure that the safety of their products continue to outweigh the risks. This article discusses in more detail the proposed elements of an acceptable Risk Evaluation and Mitigation Strategy (REMS) for any drug product, including extended-release opioid analgesics.
Related Concept Videos
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
FDA Approved Drugs: Changes to Approved Drugs
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Analysis and Critical Control Points (HACCP)
